Reply to: 'Current perspectives on the use of eplerenone for chronic central serous chorioretinopathy'

Eye (Lond). 2021 Dec;35(12):3448. doi: 10.1038/s41433-020-01327-7. Epub 2021 Jun 4.

Authors

Andrew Lotery¹, Sobha Sivaprasad², Abby O'Connell³, Barnaby Reeves³

Affiliations

¹ Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK. a.j.lotery@soton.ac.uk.
² NIHR Moorfields Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London, UK.
³ Bristol Trials Centre, Clinical Trials and Evaluation Unit, University of Bristol, Bristol Royal Infirmary, Bristol, UK.

No abstract available

Publication types

Letter
Comment

MeSH terms

Central Serous Chorioretinopathy* / drug therapy
Eplerenone / therapeutic use
Humans
Mineralocorticoid Receptor Antagonists / therapeutic use
Spironolactone / therapeutic use

Substances

Mineralocorticoid Receptor Antagonists
Spironolactone
Eplerenone

Grants and funding

MC_PC_16004/MRC_/Medical Research Council/United Kingdom